CIK 0001799448 · Non-accelerated filer<br>Smaller reporting company
Aligos Therapeutics, Inc.
Sign in to watch- Ticker
- ALGS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (800) 466-6059
- Business address
- ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-28 | McClure Matthew W. Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +16,428 | 16,428 | ||
| 2024-02-28 | Calhoun Lesley Ann See Remarks | Grant or award · Stock Option (Right to Buy) | +51,833 | 51,833 | ||
| 2024-02-28 | Calhoun Lesley Ann See Remarks | Grant or award · Stock Option (Right to Buy) | +74,998 | 74,998 | ||
| 2024-02-28 | Calhoun Lesley Ann See Remarks | Grant or award · Stock Option (Right to Buy) | +18,750 | 18,750 | ||
| 2024-02-28 | BLATT LAWRENCE Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +132,352 | 132,352 | ||
| 2024-02-28 | BLATT LAWRENCE Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +230,999 | 230,999 | ||
| 2024-02-28 | BLATT LAWRENCE Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +57,749 | 57,749 | ||
| 2024-02-28 | Symons Julian A. See Remarks | Grant or award · Stock Option (Right to Buy) | +58,822 | 58,822 | ||
| 2024-02-28 | Symons Julian A. See Remarks | Grant or award · Stock Option (Right to Buy) | +74,998 | 74,998 | ||
| 2024-02-28 | Symons Julian A. See Remarks | Grant or award · Stock Option (Right to Buy) | +18,750 | 18,750 | ||
| 2024-02-28 | Nielsen Jack Director | Grant or award · Stock Option (Right to Buy) | +4,411 | 4,411 | ||
| 2024-02-28 | Nuechterlein Carole Director | Grant or award · Stock Option (Right to Buy) | +4,411 | 4,411 | ||
| 2024-02-28 | Martell Bridget A Director | Grant or award · Stock Option (Right to Buy) | +8,823 | 8,823 | ||
| 2024-02-27 | Hirth Peter Director | Returned to the company · Stock Option (Right to Buy) | −15,000 | 0 | ||
| 2024-02-27 | Scopa James Paul Director | Returned to the company · Stock Option (Right to Buy) | −30,000 | 0 | ||
| 2024-02-27 | McClure Matthew W. Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −255,626 | 0 | ||
| 2024-02-27 | McClure Matthew W. Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −92,000 | 0 | ||
| 2024-02-27 | McClure Matthew W. Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −23,000 | 0 | ||
| 2024-02-27 | Calhoun Lesley Ann See Remarks | Returned to the company · Stock Option (Right to Buy) | −176,237 | 0 | ||
| 2024-02-27 | Calhoun Lesley Ann See Remarks | Returned to the company · Stock Option (Right to Buy) | −105,000 | 0 |
Page 3 of 12 · 238 trades